|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogiatzi P, Vindigni C, Roviello F,
Renieri A and Giordano A: Deciphering the underlying genetic and
epigenetic events leading to gastric carcinogenesis. J Cell
Physiol. 211:287–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasui W, Yokozaki H, Fujimoto J, Naka K,
Kuniyasu H and Tahara E: Genetic and epigenetic alterations in
multistep carcinogenesis of the stomach. J Gastroenterol.
35:111–115. 2000.PubMed/NCBI
|
|
5
|
Lee JH, Han SU, Cho H, et al: A novel germ
line juxtamembrane Met mutation in human gastric cancer. Oncogene.
19:4947–4953. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–2209. 2000.PubMed/NCBI
|
|
7
|
Drebber U, Baldus SE, Nolden B, et al: The
overexpression of c-met as a prognostic indicator for gastric
carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep.
19:1477–1483. 2008.PubMed/NCBI
|
|
8
|
Shiao YH, Rugge M, Correa P, Lehmann HP
and Scheer WD: p53 alteration in gastric precancerous lesions. Am J
Pathol. 144:511–517. 1994.PubMed/NCBI
|
|
9
|
Ebert MP, Yu J, Hoffmann J, et al: Loss of
beta-catenin expression in metastatic gastric cancer. J Clin Oncol.
21:1708–1714. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH
and Tang HM: Mutation analysis of tumor suppressor gene PTEN in
patients with gastric carcinomas and its impact on PI3K/AKT
pathway. Oncol Rep. 24:89–95. 2010.PubMed/NCBI
|
|
11
|
Sakata M, Kitamura YH, Sakuraba K, et al:
Methylation of HACE1 in gastric carcinoma. Anticancer Res.
29:2231–2233. 2009.PubMed/NCBI
|
|
12
|
Wu F, Shirahata A, Sakuraba K, et al:
Down-regulation of EGFL8: a novel biomarker for advanced gastric
cancer. Anticancer Res. 31:3377–3380. 2011.PubMed/NCBI
|
|
13
|
Paoletti X, Oba K, Burzykowski T, et al:
Benefit of adjuvant chemotherapy for resectable gastric cancer: a
meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.
|
|
15
|
Anderson WF, Camargo MC, Fraumeni JF Jr,
Correa P, Rosenberg PS and Rabkin CS: Age-specific trends in
incidence of non-cardia gastric cancer in US adults. JAMA.
303:1723–1728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ballinger CA, Connell P, Wu Y, Hu Z,
Thompson LJ, Yin LY and Patterson C: Identification of CHIP, a
novel tetratricopeptide repeat-containing protein that interacts
with heat shock proteins and negatively regulates chaperone
functions. Mol Cell Biol. 19:4535–4545. 1999.
|
|
17
|
Lamb JR, Tugendreich S and Hieter P:
Tetratricopeptide repeat interactions: to TPR or not to TPR? Trends
Biochem Sci. 20:257–259. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murata S, Minami Y, Minami M, Chiba T and
Tanaka K: CHIP is a chaperone-dependent E3 ligase that
ubiquitylates unfolded protein. EMBO Rep. 2:1133–1138. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Connell P, Ballinger CA, Jiang J, Wu Y,
Thompson LJ, Hohfeld J and Patterson C: The co-chaperone CHIP
regulates protein triage decisions mediated by heat-shock proteins.
Nat Cell Biol. 3:93–96. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meacham GC, Patterson C, Zhang W, Younger
JM and Cyr DM: The Hsc70 co-chaperone CHIP targets immature CFTR
for proteasomal degradation. Nat Cell Biol. 3:100–105. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kajiro M, Hirota R, Nakajima Y, et al: The
ubiquitin ligase CHIP acts as an upstream regulator of oncogenic
pathways. Nat Cell Biol. 11:312–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu T, Zhou Q, Zhou J, et al: Carboxyl
terminus of Hsp70-interacting protein (CHIP) contributes to human
glioma oncogenesis. Cancer Sci. 102:959–966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jang KW, Lee JE, Kim SY, et al: The
C-terminus of Hsp70-interacting protein promotes Met receptor
degradation. J Thorac Oncol. 6:679–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lakshmanan M, Bughani U, Duraisamy S,
Diwan M, Dastidar S and Ray A: Molecular targeting of E3 ligases -
a therapeutic approach for cancer. Expert Opin Ther Targets.
12:855–870. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou P, Fernandes N, Dodge IL, et al:
ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol
Chem. 278:13829–13837. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McDonough H and Patterson C: CHIP: a link
between the chaperone and proteasome systems. Cell Stress
Chaperones. 8:303–308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan M, Park A and Nephew KP: CHIP
(carboxyl terminus of Hsc70-interacting protein) promotes basal and
geldanamycin-induced degradation of estrogen receptor-α. Mol
Endocrinol. 19:2901–2914. 2005.PubMed/NCBI
|
|
28
|
Esser C, Scheffner M and Hohfeld J: The
chaperone-associated ubiquitin ligase CHIP is able to target p53
for proteasomal degradation. J Biol Chem. 280:27443–27448. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDonough H, Charles PC, Hilliard EG, et
al: Stress-dependent Daxx-CHIP interaction suppresses the p53
apoptotic program. J Biol Chem. 284:20649–20659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang H and Tindall DJ: Dynamic FoxO
transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li F, Xie P, Fan Y, et al: C terminus of
Hsc70-interacting protein promotes smooth muscle cell proliferation
and survival through ubiquitin-mediated degradation of FoxO1. J
Biol Chem. 284:20090–20098. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo W, Zhong J, Chang R, Hu H, Pandey A
and Semenza G: Hsp70 and CHIP selectively mediate ubiquitination
and degradation of hypoxia-inducible factor (HIF)-1α but not
HIF-2α. J Biol Chem. 285:3651–3663. 2010.PubMed/NCBI
|
